Patients with acute myeloid leukemia (AML) who achieve complete remission have improved overall survival.
In higher-risk patients who fail hypomethylating agent treatment, no induction strategy is superior to another with respect to outcomes and safety.
Consolidation therapy with a condensed schedule of high-dose cytarabine (HDAC) is superior to a standard schedule.
A higher dose of idarubicin during consolidation therapy improves leukemia-free survival without increasing non-hematologic toxicity.
Treatment with brentuximab vedotin is associated with superior clinical outcomes compared with standard of care options.
Chemotherapy-free induction with ibrutinib and rituximab is efficacious and well-tolerated among young patients.
Incorporation of bortezomib into VcR-CVAD followed by rituximab maintenance demonstrated high rates of durable remissions.
Venetoclax in combination with low-dose cytarabine appears active in older, treatment-naive patients with acute myeloid leukemia.
Rituximab maintenance following autologous hematopoietic cell transplantation prolongs survival among younger patients with mantle cell lymphoma.
Brentuximab vedotin in combination with RCHP (rituximab, cyclophosphamide, doxorubicin, and prednisone) is active as a frontline therapy.
Ultra-high risk category of patients with diffuse large B-cell lymphoma (DLBCL) who have dismal outcomes on existing therapies.
The combination of nivolumab and ibrutinib is active in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).
Clonal hematopoiesis at the time of primary cancer diagnosis was associated with a significantly increased risk of therapy-related myeloid neoplasm development.
Proposed trastuzumab biosimilar MYL-1401O demonstrated equivalent activity compared with trastuzumab among women with metastatic breast cancer.
Ofatumumab monotherapy was active and well tolerated among patients with previously untreated or relapsed Waldenström macroglobulinemia.
Pfizer's REFLECTIONS B3271002 study evaluating PF-05280014 as a potential biomarker to trastuzumab (Herceptin) met its primary endpoint.
The FDA has granted Priority Review to a sBLA that is seeking approval for pembrolizumab (Keytruda) for the treatment of Hodgkin lymphoma.
Rucaparib significantly prolongs progression-free survival among patients with BRCA-mutant or BRCA wild-type ovarian carcinomas.
Among patients with previously untreated breast cancer, endocrine therapy with fulvestrant significantly prolonged progression-free survival.
Smoking cessation improves all-cause mortality, regardless of the age at which one quits.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Watson: A Glorified Search Engine?
- Is Drugmaker Funding for Patient Groups a Hidden Culprit in Rising Drug Prices?
- Nivolumab + Ibrutinib Active in Relapsed/Refractory CLL and Richter Transformation
- Study Identifies Ultra-high Risk Category of Patients With DLBCL
- TKI-induced Cardiovascular Toxicity in Chronic Myeloid Leukemia
- Study Highlights Importance of Achieving CR After Intensive Therapy for AML
- No Induction Therapy Superior to Another for Higher-risk AML, MDS
- Condensed HDAC Schedule Superior to Standard Schedule in AML
- Higher Idarubicin Dose During Consolidation Improves Leukemia-free Survival in AML
- Brentuximab Vedotin Superior to Standard of Care Options in CTCL